ALZpath Inc. has signed a licensing agreement with Abbott to integrate its proprietary pTau217 antibody into an in vitro diagnostic test for Alzheimer's disease. This test will be developed for Abbott's widely used Alinity ci-series systems, enabling large-scale, accessible blood-based Alzheimer's detection. The pTau217 antibody is highly validated for accuracy and sensitivity, offering a less invasive and more scalable alternative to PET imaging and cerebrospinal fluid analysis. This partnership aims to expand early diagnosis and monitoring of Alzheimer's, supporting broader patient access as disease-modifying therapies grow.
The global bloodstream infection testing market is projected to grow from $876.49 million in 2025 to $1.4 billion by 2035, at a CAGR of 4.8%. Growth is fueled by rising bloodstream infection cases, increased sepsis hospitalizations, and wider adoptio...
Abbott Laboratories shares have fallen from $127.12 to $90.53 due to sector-wide rotation and concerns over its $21 billion Exact Sciences acquisition. Despite this, its diabetes franchise, led by the FreeStyle Libre glucose monitor, and medical devi...
Abbott will announce its financial results for the second quarter of 2026 on July 16 before the market opens. The company will host a live webcast of the earnings call at 8 a.m. Central time, accessible via its Investor Relations website. Abbott is a...
Abbott Laboratories reported solid Q1 2026 results with revenue growth driven by its diversified healthcare segments, including a 13.2% rise in Medical Devices and a recent $21 billion acquisition of Exact Sciences to boost diagnostics. The company h...
MiniMed has commercially launched its MiniMed 780G system integrated with Abbott's Instinct sensor and the MiniMed Go system integrated with the Instinct Go sensor in Europe. These sensors are the smallest and longest-wear options from Abbott, enhanc...
